Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

SHOCKING: Why bofa sees better entry point in ginkgo bioworks stock - What They Never Told You

Ginkgo Bioworks Holdings Inc (NYSE:DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities.

The Ginkgo Bioworks Analyst: Derik de Bruin initiated coverage of Ginkgo Bioworks with a Buy rating and $8 price target.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.